299 related articles for article (PubMed ID: 28979110)
41. Relation between systemic inflammatory markers, peripheral muscle mass, and strength in limb muscles in stable COPD patients.
Ferrari R; Caram LM; Faganello MM; Sanchez FF; Tanni SE; Godoy I
Int J Chron Obstruct Pulmon Dis; 2015; 10():1553-8. PubMed ID: 26345641
[TBL] [Abstract][Full Text] [Related]
42. IL-32 was involved in cigarette smoke-induced pulmonary inflammation in COPD.
Rong Y; Xiang XD; Li YM; Peng ZY; Li JX
Clin Respir J; 2015 Oct; 9(4):430-5. PubMed ID: 24761997
[TBL] [Abstract][Full Text] [Related]
43. Critical regulation of inflammation via class A scavenger receptor.
Xie L; Li Q; Dong R; Zhao K; Feng Y; Bao Z; Zhou M
Int J Chron Obstruct Pulmon Dis; 2018; 13():1145-1155. PubMed ID: 29695898
[TBL] [Abstract][Full Text] [Related]
44. Increased DNA damage in patients with chronic obstructive pulmonary disease who had once smoked or been exposed to biomass.
Ceylan E; Kocyigit A; Gencer M; Aksoy N; Selek S
Respir Med; 2006 Jul; 100(7):1270-6. PubMed ID: 16307872
[TBL] [Abstract][Full Text] [Related]
45. Effects of active smoking on airway and systemic inflammation profiles in patients with chronic obstructive pulmonary disease.
Pelegrino NR; Tanni SE; Amaral RA; Angeleli AY; Correa C; Godoy I
Am J Med Sci; 2013 Jun; 345(6):440-5. PubMed ID: 22874622
[TBL] [Abstract][Full Text] [Related]
46. Effects of exposure to biomass burning on pulmonary inflammatory markers and pulmonary function in individuals with COPD.
Ramos D; Proença M; Leite MR; Ferreira AD; Trevisan IB; Brígida GFS; Tacao GY; Ramos EMC
Rev Port Pneumol (2006); 2017; 23(5):273-279. PubMed ID: 28625881
[TBL] [Abstract][Full Text] [Related]
47. Circulating syndecan-1 as a novel biomarker relates to lung function, systemic inflammation, and exacerbation in COPD.
Li D; Wu Y; Guo S; Qin J; Feng M; An Y; Zhang J; Li Y; Xiong S; Zhou H; Zeng Q; Chen L; Wen F
Int J Chron Obstruct Pulmon Dis; 2019; 14():1933-1941. PubMed ID: 31695352
[TBL] [Abstract][Full Text] [Related]
48. Determinants of systemic vascular function in patients with stable chronic obstructive pulmonary disease.
Eickhoff P; Valipour A; Kiss D; Schreder M; Cekici L; Geyer K; Kohansal R; Burghuber OC
Am J Respir Crit Care Med; 2008 Dec; 178(12):1211-8. PubMed ID: 18836149
[TBL] [Abstract][Full Text] [Related]
49. Tumor necrosis factor receptor 2 as a possible marker of COPD in smokers and ex-smokers.
Caram LMO; Ferrari R; Nogueira DL; Oliveira M; Francisqueti FV; Tanni SE; Corrêa CR; Godoy I
Int J Chron Obstruct Pulmon Dis; 2017; 12():2015-2021. PubMed ID: 28744116
[TBL] [Abstract][Full Text] [Related]
50. Prevalence of chronic obstructive pulmonary disease and associated risk factors in Uganda (FRESH AIR Uganda): a prospective cross-sectional observational study.
van Gemert F; Kirenga B; Chavannes N; Kamya M; Luzige S; Musinguzi P; Turyagaruka J; Jones R; Tsiligianni I; Williams S; de Jong C; van der Molen T
Lancet Glob Health; 2015 Jan; 3(1):e44-51. PubMed ID: 25539969
[TBL] [Abstract][Full Text] [Related]
51. Asthma-COPD overlap is not a homogeneous disorder: further supporting data.
Pérez-de-Llano L; Cosio BG;
Respir Res; 2017 Nov; 18(1):183. PubMed ID: 29096609
[TBL] [Abstract][Full Text] [Related]
52. Comparison of inflammation biomarkers among chronic obstructive pulmonary disease groups: A cross sectional study.
Yazici O; Gulen ST; Yenisey C; Eryilmaz U; Abas BI; Polatli M
Niger J Clin Pract; 2020 Jun; 23(6):817-824. PubMed ID: 32525117
[TBL] [Abstract][Full Text] [Related]
53. Inflammatory biomarkers and exacerbations in chronic obstructive pulmonary disease.
Thomsen M; Ingebrigtsen TS; Marott JL; Dahl M; Lange P; Vestbo J; Nordestgaard BG
JAMA; 2013 Jun; 309(22):2353-61. PubMed ID: 23757083
[TBL] [Abstract][Full Text] [Related]
54. In vitro modeling of COPD inflammation and limitation of p38 inhibitor - SB203580.
Meng A; Zhang X; Wu S; Wu M; Li J; Yan X; Kopec-Harding K; Wu J
Int J Chron Obstruct Pulmon Dis; 2016; 11():909-17. PubMed ID: 27199554
[TBL] [Abstract][Full Text] [Related]
55. Bacterial load and inflammatory response in sputum of alpha-1 antitrypsin deficiency patients with COPD.
Balbi B; Sangiorgi C; Gnemmi I; Ferrarotti I; Vallese D; Paracchini E; Delle Donne L; Corda L; Baderna P; Corsico A; Carone M; Brun P; Cappello F; Ricciardolo FL; Ruggeri P; Mumby S; Adcock IM; Caramori G; Di Stefano A
Int J Chron Obstruct Pulmon Dis; 2019; 14():1879-1893. PubMed ID: 31686800
[TBL] [Abstract][Full Text] [Related]
56. Increased serum levels of lipocalin-1 and -2 in patients with stable chronic obstructive pulmonary disease.
Wang XR; Li YP; Gao S; Xia W; Gao K; Kong QH; Qi H; Wu L; Zhang J; Qu JM; Bai CX
Int J Chron Obstruct Pulmon Dis; 2014; 9():543-9. PubMed ID: 24920892
[TBL] [Abstract][Full Text] [Related]
57. Systemic inflammation in patients with COPD and pulmonary hypertension.
Joppa P; Petrasova D; Stancak B; Tkacova R
Chest; 2006 Aug; 130(2):326-33. PubMed ID: 16899829
[TBL] [Abstract][Full Text] [Related]
58. Prevalence of Major Comorbidities in Chronic Obstructive Pulmonary Disease Caused by Biomass Smoke or Tobacco.
Golpe R; Martín-Robles I; Sanjuán-López P; Cano-Jiménez E; Castro-Añon O; Mengual-Macenlle N; Pérez-de-Llano L
Respiration; 2017; 94(1):38-44. PubMed ID: 28456807
[TBL] [Abstract][Full Text] [Related]
59. Hydrogen coadministration slows the development of COPD-like lung disease in a cigarette smoke-induced rat model.
Liu X; Ma C; Wang X; Wang W; Li Z; Wang X; Wang P; Sun W; Xue B
Int J Chron Obstruct Pulmon Dis; 2017; 12():1309-1324. PubMed ID: 28496315
[TBL] [Abstract][Full Text] [Related]
60. Dynamic pulmonary hyperinflation and low grade systemic inflammation in stable COPD patients.
Gatta D; Aliprandi G; Pini L; Zanardini A; Fredi M; Tantucci C
Eur Rev Med Pharmacol Sci; 2011 Sep; 15(9):1068-73. PubMed ID: 22013730
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
